The benchmark indices, Sensex and Nifty, on Thursday, December 23, 2021, gained more than half a per cent in volatile sessions. The BSE Sensex rose 385 points, or 0.68 per cent to trade at 57,315. Get more Markets News and Business News on Zee Business.
Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Biocon Biologics posts 53% growth in revenues at ₹664 crore for Q4FY21
April 29, 2021
For the full year, revenues have grown 21 per cent to ₹2,800 crore
Revenues of Biocon Biologics Limited, a subsidiary of Biocon Limited, grew by 53 per cent year-on-year (y-o-y) at ₹664 crore for fourth quarter of financial year 2021-22, mainly driven by emerging markets business. Q4FY21 EBITDA stood at ₹164 crore and EBITDA margin was 25 per cent.
Commenting on company’s performance, Dr Arun Chandavarkar, Managing Director, Biocon Biologics Ltd, said, “We have reported a revenue growth of 53 per cent y-o-y at ₹664 crore for Q4FY21, led by a strong growth of our emerging markets business, supported by market share gains for Pegfilgrastim and Trastuzumab biosimilars in the developed markets, and contributions from Insulin Glargine introduced in the US earlier this fiscal. The marketing authorisation approvals for our biosimilar insulin Aspart and biosimilar Bevacizumab in the EU au
FY21 Revenue Up 14% at Rs 7,360 Cr for Biocon
FY21 Revenue Up 14% at Rs 7,360 Cr for Biocon
29 April 2021 | News FY21 Consolidated Revenue grew 14% to Rs 7,360 Crore from Rs 6,462 Crore in FY20
Image credit- shutterstock.com
Biocon has announced its consolidated financial results for the fourth quarter and the fiscal year ended March 31, 2021.
Commenting on the results, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, said: In Q4FY21 our revenues grew 26% YoY to Rs 2,044 Crore driven by our Biosimilars, Research Services and Generics businesses. On a full-year basis, we reported a revenue growth of 14% led by Biosimilars which grew by 21%, Research Services by 9% and Generics by 6%. For FY21, EBITDA was at Rs 1,907 Crore and core EBITDA margins at 33%. Our determination to keep investing in science to stay a step ahead of the pandemic is reflected in the 19% rise in our Gross R&D spends in the year.